CN111991524A - Traditional Chinese medicine composition for convalescent period of neocoronary pneumonia infection and preparation method thereof - Google Patents
Traditional Chinese medicine composition for convalescent period of neocoronary pneumonia infection and preparation method thereof Download PDFInfo
- Publication number
- CN111991524A CN111991524A CN202010890639.7A CN202010890639A CN111991524A CN 111991524 A CN111991524 A CN 111991524A CN 202010890639 A CN202010890639 A CN 202010890639A CN 111991524 A CN111991524 A CN 111991524A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- convalescent period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 53
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 19
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 19
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 16
- 244000268590 Euryale ferox Species 0.000 claims abstract description 16
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 16
- 244000269722 Thea sinensis Species 0.000 claims abstract description 16
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 16
- 235000020279 black tea Nutrition 0.000 claims abstract description 16
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 15
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 15
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 15
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 15
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 15
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 241000208340 Araliaceae Species 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 8
- 244000249214 Chlorella pyrenoidosa Species 0.000 claims description 8
- 235000007091 Chlorella pyrenoidosa Nutrition 0.000 claims description 8
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 8
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims 2
- 239000009609 fructus phyllanthi Substances 0.000 claims 1
- 229940107131 ginseng root Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000009471 action Effects 0.000 abstract description 6
- 230000007246 mechanism Effects 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 description 14
- 239000000843 powder Substances 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 241000711573 Coronaviridae Species 0.000 description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 2
- 229920002079 Ellagic acid Polymers 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- HVXHJNVYRXRHNX-UHFFFAOYSA-N Garcinone B Chemical compound O1C(C)(C)C=CC2=C(C(=O)C=3C(=CC(O)=C(C=3O)CC=C(C)C)O3)C3=CC(O)=C21 HVXHJNVYRXRHNX-UHFFFAOYSA-N 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- VABYUUZNAVQNPG-UHFFFAOYSA-N Piperlongumine Natural products COC1=C(OC)C(OC)=CC(C=CC(=O)N2C(C=CCC2)=O)=C1 VABYUUZNAVQNPG-UHFFFAOYSA-N 0.000 description 2
- WHAAPCGHVWVUEX-UHFFFAOYSA-N Piperlonguminine Natural products CC(C)CNC(=O)C=CC=CC1=CC=C2OCOC2=C1 WHAAPCGHVWVUEX-UHFFFAOYSA-N 0.000 description 2
- VABYUUZNAVQNPG-BQYQJAHWSA-N Piplartine Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2C(C=CCC2)=O)=C1 VABYUUZNAVQNPG-BQYQJAHWSA-N 0.000 description 2
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000004132 ellagic acid Nutrition 0.000 description 2
- 229960002852 ellagic acid Drugs 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 2
- 229940116852 myricetin Drugs 0.000 description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 2
- 235000007743 myricetin Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 1
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- PYXFVCFISTUSOO-VUFVRDRTSA-N (20R)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-VUFVRDRTSA-N 0.000 description 1
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 1
- YSTPAHQEHQSRJD-UHFFFAOYSA-N 3-Carvomenthenone Chemical compound CC(C)C1CCC(C)=CC1=O YSTPAHQEHQSRJD-UHFFFAOYSA-N 0.000 description 1
- LNCSXXRCEFAYFK-XNTDXEJSSA-N 4,5-dimethoxy-2-prop-2-enyl-4-[(e)-1-(3,4,5-trimethoxyphenyl)prop-1-en-2-yl]cyclohexa-2,5-dien-1-one Chemical compound COC1=CC(=O)C(CC=C)=CC1(OC)C(\C)=C\C1=CC(OC)=C(OC)C(OC)=C1 LNCSXXRCEFAYFK-XNTDXEJSSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 101150060184 ACHE gene Proteins 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 240000004510 Agastache rugosa Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- COZMWVAACFYLBI-UHFFFAOYSA-N Chebulic acid Natural products OC1=C(O)C(O)=C2C(C(CC(=O)O)C(O)=O)C(C(O)=O)OC(=O)C2=C1 COZMWVAACFYLBI-UHFFFAOYSA-N 0.000 description 1
- 229920002361 Chebulic acid Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 description 1
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 102100029951 Estrogen receptor beta Human genes 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- LNCSXXRCEFAYFK-UHFFFAOYSA-N Hancinone C Natural products COC1=CC(=O)C(CC=C)=CC1(OC)C(C)=CC1=CC(OC)=C(OC)C(OC)=C1 LNCSXXRCEFAYFK-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 101000934320 Homo sapiens Cyclin-A2 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 1
- 101001128158 Homo sapiens Nanos homolog 2 Proteins 0.000 description 1
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 description 1
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
- 101000602930 Homo sapiens Nuclear receptor coactivator 2 Proteins 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 101000655897 Homo sapiens Serine protease 1 Proteins 0.000 description 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 101150003941 Mapk14 gene Proteins 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102100037226 Nuclear receptor coactivator 2 Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 102100032491 Serine protease 1 Human genes 0.000 description 1
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- FSLPMRQHCOLESF-SFMCKYFRSA-N alpha-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C FSLPMRQHCOLESF-SFMCKYFRSA-N 0.000 description 1
- SJMCNAVDHDBMLL-UHFFFAOYSA-N alpha-amyrin Natural products CC1CCC2(C)CCC3(C)C(=CCC4C5(C)CCC(O)CC5CCC34C)C2C1C SJMCNAVDHDBMLL-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- COZMWVAACFYLBI-XJEVXTIOSA-N chebulic acid Chemical compound OC1=C(O)C(O)=C2[C@H]([C@H](CC(=O)O)C(O)=O)[C@@H](C(O)=O)OC(=O)C2=C1 COZMWVAACFYLBI-XJEVXTIOSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- OXVUXGFZHDKYLS-QUFHAEKXSA-N euscaphic acid Chemical compound C1[C@@H](O)[C@@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C OXVUXGFZHDKYLS-QUFHAEKXSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- ACXGEQOZKSSXKV-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCC(O)=O ACXGEQOZKSSXKV-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930006968 piperitone Natural products 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for the convalescent period of neocoronary pneumonia infection, which is prepared from the following raw materials in parts by weight: 0.5-5 parts of ginseng, 1-30 parts of Chinese yam, 2-15 parts of rhizoma polygonati, 1-15 parts of gordon euryale seed, 2-30 parts of coix seed, 3-10 parts of dried orange peel, 1-18 parts of emblic leafflower fruit, 1-15 parts of silk reeling flower and 1-10 parts of black tea. And a preparation method of the traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection is provided. The research result of the formula component-target point-pharmacological action mechanism network of the traditional Chinese medicine composition for the convalescent period of the new coronary pneumonia infection is consistent with the link of the main treatment disease, and the modern precise medical principle is met. Meanwhile, the product has low cost and meets the requirement of industrialized production.
Description
Technical Field
The invention belongs to the technical field of health care products, and particularly relates to a traditional Chinese medicine composition for treating neocoronary pneumonia in a recovery period and a preparation method thereof.
Background
The novel Coronavirus pneumonia (COVID-19, New CoV pneumonia) is an Acute infectious disease caused by a newly discovered Coronavirus (Severe Acute Respiratory Syndrome-Coronavir-2, SARS-CoV-2) infection. The disease is taken as an acute respiratory infectious disease and is incorporated into a B infectious disease specified in the infection prevention and treatment law of the people's republic of China, and is managed according to the A infectious disease. By adopting a series of preventive control and medical treatment measures, the rising momentum of the epidemic situation in China is restrained. With the deepening of clinical manifestation and pathological understanding of the disease and the accumulation of diagnosis and treatment experiences, new technologies and new methods for prevention, detection and treatment are urgently needed to be developed and applied in order to further strengthen early diagnosis and early treatment of the disease, improve the cure rate and reduce the death rate.
Although the patients who are discharged have reached the discharge standard with improvement of inflammation and disappearance of infectivity as main indicators, a considerable part of the patients still have clinical discomfort. After statistics, a research team in Dongzhou university of traditional Chinese medicine hospital discovers that 67% of patients who are discharged from the hospital and have at least 1 respiratory system discomfort symptom such as mild dry cough and short breath. With the adoption of scientific prevention and control measures in China and the combined efforts of all epidemic prevention personnel, the epidemic situation is effectively controlled, most of cases are cured and discharged, and the rehabilitation treatment of patients in the convalescent period is expected to gradually become a new treatment requirement.
In the latest version of diagnosis and treatment scheme of Xinguan pneumonia, the recommended prescription for convalescent patients is 9 g of rhizoma pinellinae praeparata, 10g of dried orange peel, 15g of radix codonopsitis, 30g of radix astragali preparata, 10g of fried rhizoma atractylodis macrocephalae, 15g of poria cocos, 10g of wrinkled gianthyssop herb, 6g of fructus amomi (added later) and 6g of liquorice. The study of Chinese medicine prescription in convalescent period released by health administration before 3/5/2020 for prevention and treatment of new coronary pneumonia by scholars mainly comprises deficiency tonifying medicine, heat clearing medicine and dampness eliminating medicine, and the first 5 high-frequency medicines are Glycyrrhrizae radix, Poria, pericarpium Citri Tangerinae, radix Ophiopogonis and radix astragali respectively. However, the new coronary pneumonia has a long course of disease and is easy to consume healthy qi, the recovery period has the characteristics of weak healthy qi and incomplete remaining pathogens, and the common clinical manifestations include short breath, lassitude, hypodynamia, poor appetite, nausea, fullness, weakness of stool, loose stool, pale and fat tongue, white and greasy tongue coating and the like. Therefore, improvement of subsequent treatment of patients in convalescent stage of new coronary pneumonia is of considerable importance.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a traditional Chinese medicine composition for the convalescent period of neocoronary pneumonia infection and a preparation method thereof.
The invention provides a traditional Chinese medicine composition for the convalescent period of neocoronary pneumonia infection, which is prepared from the following raw materials in parts by weight:
0.5 to 5 parts of ginseng,
1-30 parts of Chinese yam,
2-15 parts of rhizoma polygonati,
1-15 parts of gordon euryale seed,
2-30 parts of coix seed,
3-10 parts of dried orange peel,
1-18 parts of emblic leafflower fruit,
1-15 parts of silk reeling flower,
1-10 parts of black tea.
And a preparation method of the traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection, which comprises the following steps:
weighing the raw materials according to the weight parts of the traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection, mixing Chinese yam, rhizoma polygonati, gordon euryale seed, coix seed, dried orange peel, emblic leafflower fruit, filature flower and black tea, adding 5-20 parts by mass of water to soak for 15-60 minutes, heating and reflux extracting for 0.5-2 hours, and filtering with 80-200 meshes to obtain a first extract;
adding 5-20 times of water by mass into the medicine residues, performing reflux extraction for 0.5-2 hours, and filtering by 80-200 meshes to obtain a second extracting solution;
mixing the first extract and the second extract, concentrating, and adding Ginseng radix to obtain the Chinese medicinal composition for treating convalescent stage of neocoronary pneumonia infection.
The traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection consists of ginseng, Chinese yam, rhizoma polygonati, gorgon fruit, coix seed, dried orange peel, emblic leafflower fruit, filature flower and black tea extracts, has the effects of tonifying qi and yin, strengthening spleen and tonifying lung, and is used for treating the convalescent period of a patient with the neocoronary pneumonia due to lung-spleen qi deficiency. The traditional Chinese medicine composition has the characteristics of reasonable formula, remarkable effect, definite active ingredients, clear action target and pharmacological effect, wide raw materials, low cost, excellent preparation, convenient taking and the like, is suitable for patients with new coronary pneumonia with lung and spleen qi deficiency in convalescent period, has the effects of tonifying qi and nourishing body fluid, tonifying lung and spleen, and relieves clinical discomfort symptoms.
Drawings
Fig. 1 is a network diagram of the association between the traditional Chinese medicine raw materials, active ingredients and action targets of the traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection provided by the embodiment of the invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in further detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
The embodiment of the invention provides a traditional Chinese medicine composition for a convalescent period of neocoronary pneumonia infection, which is prepared from the following raw materials in parts by weight:
0.5 to 5 parts of ginseng,
1-30 parts of Chinese yam,
2-15 parts of rhizoma polygonati,
1-15 parts of gordon euryale seed,
2-30 parts of coix seed,
3-10 parts of dried orange peel,
1-18 parts of emblic leafflower fruit,
1-15 parts of silk reeling flower,
1-10 parts of black tea.
Preferably, the preparation raw materials of the traditional Chinese medicine composition for the convalescent period of the new coronary pneumonia infection also comprise 1-6 parts of chlorella pyrenoidosa, 1-6 parts of trehalose and 1-3 parts of mannose oligomer. The low-polymannan mannose can directly enter into large intestine to be utilized by Bacillus bifidus, and can promote proliferation of Bacillus bifidus and simultaneously produce various organic acids. The pH value of the intestinal tract is reduced, the growth of harmful bacteria is inhibited, and the probiotics are greatly proliferated in the intestinal tract, so that the intestinal function is adjusted. More preferably, the chlorella pyrenoidosa is 6 parts, the trehalose is 6 parts, and the mannose oligomer is 1.5 parts.
More preferably, the traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection is prepared from the following raw materials in parts by weight: 2-4 parts of ginseng, 8-10 parts of Chinese yam, 8-10 parts of rhizoma polygonati, 8-10 parts of gordon euryale seed, 8-12 parts of coix seed, 8-10 parts of dried orange peel, 8-10 parts of emblic leafflower fruit, 8-10 parts of silk reeling flower and 4-6 parts of black tea. More specifically, the traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection is prepared from the following raw materials in parts by weight: 3 parts of ginseng, 9 parts of Chinese yam, 9 parts of rhizoma polygonati, 9 parts of gordon euryale seed, 10 parts of coix seed, 9 parts of dried orange peel, 9 parts of emblic leafflower fruit, 9 parts of silk reeling flower and 5 parts of black tea.
The traditional Chinese medicine composition for the recovery period of the neocoronary pneumonia infection is composed of ginseng, Chinese yam, sealwort, gordon euryale seed, coix seed, dried orange peel, emblic leafflower fruit, filature flower, black tea, chlorella pyrenoidosa, trehalose and oligomannose, and is mainly used for patients with the recovery period of the neocoronary pneumonia (deficiency of lung and spleen qi), mild cough, short breath, mental fatigue, juicing when in movement, anorexia, pale tongue with white and moist fur and slow and weak pulse. 102 potential active ingredients are screened in the cyber pharmacological research, and mainly comprise Ginsenoside (3R) -Protopanaxadiol, (20S) -Protopanaxadiol, (20R) -Protopanaxadiol, Ginsenoside rh2, Ginsenoside rf, Ginsenoside Rg1, Ginsenoside Rb1, Ginsenoside-Rd and Ginsenoside Re; adenosine (Adenosine), diosgenin (diosgenin), Garcinone B (forrestinol B), hancinone C (piperitone C), piperlongumine (piperlongumine), Uracil (Uracil); caprylic acid (caprylic acid), ergosterol (ergosterol), linolenic acid (linolenic acid), chebulic acid (kojic acid), ellagic acid (ellagic acid), epigalloatechin gate (Epigallocatechin gallate), galilic acid (Gallic acid), alpha-amyrin (alpha-coumarol); heperidin (hesperidin), naringenin (naringin); caffeine, Epigallocatechin, catechin gate (catechin gallate), Epigallocatechin gate (gallocatechin gallate); euscapic Acid (roxburgh Acid), protocathechuic Acid (protocatechuic Acid), Myricetin (Myricetin), succidic Acid (Succinic Acid), Citric Acid (Citric Acid), malic Acid (malic Acid), gallic Acid (gallic Acid), caffeic Acid (caffeic Acid), and ursolic Acid. The target prediction is carried out on the active ingredients, 264 targets are screened together, and the active ingredients mainly comprise AR, PTGS2, ESR1, DPP4, NOS2, CDK2, CA2, PRSS1, PTPN1, PTGS1, PIM1, F2, PPARG, ESR2, CCNA2, NCOA2, GSK3B, NOS3, ACHE, MAPK14 and the like. A large number of pharmacological research results show that the traditional Chinese medicine composition for the convalescent period of the new coronary pneumonia has the pharmacological functions of improving the lung function, resisting viruses, enhancing the immunity, promoting the digestion and absorption, improving the negative nitrogen balance and the like, so that the early rehabilitation of patients in the convalescent period of the new coronary pneumonia is promoted. The system in table 1 reveals the pharmacodynamic active substance basis, action target and molecular mechanism of the traditional Chinese medicine composition for promoting the rehabilitation of patients in the convalescent period of new coronary pneumonia.
The specific functions of the components are shown in the table 1:
TABLE 1
Qi deficiency is the core pathogenesis of the convalescent stage of new coronary pneumonia, and the diagnosis and treatment scheme (trial seventh edition) of novel coronavirus pneumonia and the Chinese medical rehabilitation guidance suggestion (trial) of the convalescent stage of novel coronavirus pneumonia both propose the point. The qi deficiency of most patients in the convalescent period of the new coronary pneumonia is manifested by cough, shortness of breath, hypodynamia, abdominal distension, anorexia, and the like. Tonifying when deficiency occurs is the main principle of convalescent treatment. The pathogenesis evolution process of the new coronary pneumonia is as follows: epidemic qi is pathogenic factors of both wind-cold-dampness, and has rapid and easy-to-infect ability due to natural wind, although it is cold-dampness nature and good in nature crime, and it enters the lung from the upper jiao; the lung is in the upper energizer, such as Huagai, and is warmed by heart fire and receives the qi of ying-wei to control and distribute qi and blood. Cold-dampness entering lung directly impairs lung yang, and is indicated for dyspnea and dyspnea due to abnormal qi, blood and body fluids distribution, and accumulation in lung to form phlegm and blood stasis; when yang qi is exuberant, or cold-dampness of lung is directly relieved for curing, when yang qi is exuberant, healthy qi and pathogenic qi struggle with lung and high fever, and when yang qi is deficient, lung cold-dampness is hard to relieve for a long time or after noon hot flash occurs; yang qi resisting pathogen gradually releases cold pathogen, dampness is sticky and can stagnate to transform into heat, or descend to the spleen and stomach of middle energizer along the triple energizer, or to the middle energizer directly, so it is uncomfortable to have abdominal distension and loose stool; the soil is the mother-of-jin, the child-organ comes from the evil, the disease is gradually weakened, and the disease can be cured by the strong spleen and stomach; during the convalescent period, the symptoms of qi deficiency of lung and spleen are common, and the treatment is mainly to tonify qi and strengthen spleen.
The traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection provided by the invention takes ginseng which can tonify primordial qi as a main material, and is added with spleen-invigorating, phlegm-resolving, stomach-harmonizing and digestion-promoting medicines, recovers the functions of various viscera by adjusting the acquired basis, and can tonify lung qi, effectively improves the symptoms of short breath, fatigue and hypodynamia, poor appetite and nausea, fullness, no strength of stool, loose stool, pale and fat tongue, white and greasy tongue coating and the like caused by qi deficiency, is suitable for treating the patient with the convalescent period of the neocoronary pneumonia, and is beneficial to the comprehensive rehabilitation of the patient. The traditional Chinese medicine composition has clear effective components, clear action target network and clear participating physiological/pathological process, and as shown in figure 1, the research result of the component-target-pharmacological action mechanism network of the formula conforms to the requirements of patients in the infection recovery period.
The embodiment of the invention also provides a preparation method of the traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection, which comprises the following steps:
weighing the raw materials according to the weight parts of the traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection, mixing Chinese yam, rhizoma polygonati, gordon euryale seed, coix seed, dried orange peel, emblic leafflower fruit, filature flower and black tea, adding 5-20 parts by mass of water to soak for 15-60 minutes, heating and reflux extracting for 0.5-2 hours, and filtering with 100 meshes to obtain a first extracting solution;
adding 5-20 times of water by mass into the medicine residues, performing reflux extraction for 0.5-2 hours, and filtering by a 100-mesh sieve to obtain a second extracting solution;
mixing the first extract and the second extract, concentrating, and adding Ginseng radix to obtain the Chinese medicinal composition for treating convalescent stage of neocoronary pneumonia infection.
Preferably, the Chinese yam, the sealwort, the gorgon fruit, the coix seed, the dried orange peel, the emblic leafflower fruit, the filature flower and the black tea are mixed, added with 8-15 times of water by mass for soaking for 20-40 minutes, heated and refluxed for extraction for 0.5-2 hours, and filtered by a sieve of 100 meshes to obtain a first extracting solution;
adding 8-15 times of water by mass into the medicine residues, heating, refluxing and extracting for 0.5-2 hours, and filtering by a 100-mesh sieve to obtain a second extracting solution.
Preferably, the ginseng is used after being subjected to superfine grinding.
Specifically, the first extract and the second extract are combined, concentrated at 70 ℃ under reduced pressure until the relative density is about 1.08 to obtain a concentrated solution, maltodextrin is added into the concentrated solution, stirred uniformly, and spray-dried (the air inlet temperature of a nozzle is set to be 150 ℃, and the air outlet temperature is 80 ℃) to obtain extract powder. Adding Ginseng radix micropowder, Chlorella pyrenoidosa, trehalose, and mannose oligomer into the extract powder, and mixing; subpackaging with 10g per bag to obtain the solid beverage.
In addition, mixing the above extract powder with Ginseng radix micropowder, Chlorella pyrenoidosa, trehalose, and mannose oligomer, adding 85% ethanol, granulating, drying at 70 deg.C, grading, and tabletting; or adopting appropriate adjuvants such as maltodextrin, corn starch, wheat flour, and protein powder, performing dry granulation or directly tabletting, and making into appropriate tablet.
The final form of the product can be various, including powder, granule, tablet, honeyed pill, soft extract, oral liquid, syrup, etc. In the preparation process, the drying mode can be spray drying, vacuum drying, freeze drying and the like; the granulation method can be dry granulation, wet granulation, one-step granulation and the like. Preferably, the concentrated solution is dried under reduced pressure, dried by spraying, and quickly dried to obtain powder, so that damage to various components is reduced, and support is provided for effectiveness of the product.
By adopting the method acceptable by relevant laws and regulations of pharmacy, food, health care products and the like, the traditional Chinese medicine components of the traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection can be extracted, concentrated, dried or crushed, further processed into products, the effective components of the compound are reserved, and the products are prepared into suitable administration forms (including dosage forms such as granules, powder, oral liquid, tablets and the like) or food forms such as tabletting candies, meal powder, solid beverages and the like, so that the requirements of the market on relevant products are met, and the invention belongs to the protection scope.
The following describes the above-mentioned traditional Chinese medicine composition for the convalescent period of neocoronary pneumonia infection and the preparation method thereof by means of specific formulation and preparation process examples.
Example 1:
weighing 9kg of Chinese yam, 9kg of rhizoma polygonati, 9kg of gordon euryale seed, 10kg of coix seed, 9kg of dried orange peel, 9kg of emblic leafflower fruit, 9kg of filature flower and 5kg of black tea according to the weight parts of the traditional Chinese medicine composition for the recovery period of the neocoronary pneumonia infection, mixing, adding 720L of water for soaking for 30 minutes, heating, refluxing and extracting for 1 hour, and filtering by 100 meshes to obtain a first extracting solution;
adding 720L water into the residue, reflux extracting for 1 hr, and filtering with 100 mesh filter to obtain second extractive solution;
mixing the first extractive solution and the second extractive solution, concentrating at 70 deg.C under reduced pressure to relative density of about 1.08 to obtain concentrated solution, adding maltodextrin, stirring, spray drying (nozzle air inlet temperature is 150 deg.C, air outlet temperature is 80 deg.C) to obtain extract powder, adding Ginseng radix 3kg, Chlorella pyrenoidosa 6kg, trehalose 6kg, and oligomannose 1.5kg into the extract powder, and mixing; subpackaging with 10 g/bag to obtain solid beverage powder.
Example 2:
10 patients in the convalescent period of the new coronary pneumonia infection are selected to take the solid beverage powder prepared in the example 1 every day, and after continuous taking for two weeks, no adverse reaction exists, and 7 patients have remarkable relief of uncomfortable symptoms.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Claims (8)
1. A traditional Chinese medicine composition for the convalescent period of neocoronary pneumonia infection is characterized by being prepared from the following raw materials in parts by weight:
0.5 to 5 parts of ginseng,
1-30 parts of Chinese yam,
2-15 parts of rhizoma polygonati,
1-15 parts of gordon euryale seed,
2-30 parts of coix seed,
3-10 parts of dried orange peel,
1-18 parts of emblic leafflower fruit,
1-15 parts of silk reeling flower,
1-10 parts of black tea.
2. The traditional Chinese medicine composition for the convalescent period of neocoronary pneumonia infection of claim 1, which is prepared from the following raw materials in parts by weight:
2-4 parts of ginseng,
8-10 parts of Chinese yam,
8-10 parts of rhizoma polygonati,
8-10 parts of gordon euryale seed,
8-12 parts of coix seeds, namely,
8-10 parts of dried orange peel,
8-10 parts of emblic leafflower fruit,
8-10 parts of silk reeling flowers,
4-6 parts of black tea.
3. The traditional Chinese medicine composition for the convalescent period of neocoronary pneumonia infection of claim 2, which is prepared from the following raw materials in parts by weight:
3 parts of ginseng, namely ginseng root,
9 parts of Chinese yam, namely,
9 parts of sealwort, 9 parts of,
9 parts of gorgon fruit, namely,
10 parts of coix seed, namely 10 parts of coix seed,
9 parts of dried orange peel, namely dried orange peel,
9 parts of emblic leafflower fruit, namely,
9 parts of silk reeling flower,
5 parts of black tea.
4. The traditional Chinese medicine composition for the convalescent period of the new coronary pneumonia infection of claim 1, wherein the raw materials for preparing the traditional Chinese medicine composition further comprise chlorella pyrenoidosa, trehalose and oligomannose.
5. A preparation method of a traditional Chinese medicine composition for the convalescent period of neocoronary pneumonia infection is characterized by comprising the following steps:
weighing the raw materials according to the weight parts of the traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection according to any one of claims 1 to 3, mixing Chinese yam, rhizoma polygonati, gorgon fruit, coix seed, dried orange peel, emblic leafflower fruit, filature flower and black tea, adding 5-20 times of water by mass, soaking for 15-60 minutes, heating, refluxing and extracting for 0.5-2 hours, and filtering with 80-200 meshes to obtain a first extracting solution;
adding 5-20 times of water by mass into the medicine residues, performing reflux extraction for 0.5-2 hours, and filtering by 80-200 meshes to obtain a second extracting solution;
mixing the first extract and the second extract, concentrating, and adding Ginseng radix to obtain the Chinese medicinal composition for treating convalescent stage of neocoronary pneumonia infection.
6. The method for preparing a Chinese medicinal composition for the convalescent period of neocoronary pneumonia infection as claimed in claim 5, wherein rhizoma Dioscoreae, rhizoma Polygonati, semen euryales, semen Coicis, pericarpium Citri Reticulatae, fructus Phyllanthi, filature flower and black tea are mixed, and soaked in 8-15 times of water for 20-40 min.
7. The preparation method of the traditional Chinese medicine composition for the convalescent period of the neocoronary pneumonia infection, which is disclosed by claim 5, is characterized in that 8-15 times of water in parts by mass of medicine residues is added.
8. The method of claim 5, wherein the addition of the ginseng is followed by the addition of chlorella pyrenoidosa, trehalose, and oligomannose.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010698799 | 2020-07-17 | ||
| CN2020106987991 | 2020-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111991524A true CN111991524A (en) | 2020-11-27 |
Family
ID=73466304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010890639.7A Pending CN111991524A (en) | 2020-07-17 | 2020-08-29 | Traditional Chinese medicine composition for convalescent period of neocoronary pneumonia infection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111991524A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113616600A (en) * | 2021-08-05 | 2021-11-09 | 广东汇群中药饮片股份有限公司 | Traditional Chinese medicine compound granule for treating spleen-lung qi deficiency and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107551230A (en) * | 2016-07-01 | 2018-01-09 | 蔡晓静 | A kind of pharmaceutical composition for treating children Streptococcus convalescence asthenia of pulmonosplenic qi card |
-
2020
- 2020-08-29 CN CN202010890639.7A patent/CN111991524A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107551230A (en) * | 2016-07-01 | 2018-01-09 | 蔡晓静 | A kind of pharmaceutical composition for treating children Streptococcus convalescence asthenia of pulmonosplenic qi card |
Non-Patent Citations (5)
| Title |
|---|
| 刘建文等: "《养生保健的全营养素-小球藻》", 31 January 2008, 中国社会出版社 * |
| 刘景圣等: "《功能性食品》", 28 February 2005, 中国农业出版社 * |
| 周幸来等: "《常用中药临证禁忌》", 29 February 2016, 金盾出版社 * |
| 姜锡瑞等: "《生物发酵产业技术》", 30 May 2016, 中国轻工业出版社 * |
| 李建生等: "河南省新型冠状病毒肺炎中医辨证治疗思路与方法", 《中医学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113616600A (en) * | 2021-08-05 | 2021-11-09 | 广东汇群中药饮片股份有限公司 | Traditional Chinese medicine compound granule for treating spleen-lung qi deficiency and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103829238A (en) | Blood lipid lowering health food and preparation method thereof | |
| CN105012452A (en) | New application of clausena lansium leaves | |
| CN112515014A (en) | Kudzuvine root polysaccharide sweet zong black tea and preparation method thereof | |
| CN111991524A (en) | Traditional Chinese medicine composition for convalescent period of neocoronary pneumonia infection and preparation method thereof | |
| CN104758900A (en) | Traditional Chinese medicine for treating acute pancreatitis | |
| CN104173651A (en) | Orally-taken traditional Chinese medicine pill for treating dysentery | |
| CN104642605A (en) | Detoxifying tea and preparation method thereof | |
| CN104510937A (en) | Traditional Chinese medicinal formula for treating infantile asthma and preparation method for paste of traditional Chinese medicinal formula | |
| CN110101818A (en) | A kind of Chinese medicine for treating diabetes | |
| KR101866915B1 (en) | Manufacturing method for extracts granule of oriental herb medicine materials for improving constipation and extracts granule manufactured by the same | |
| CN106173604A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Rhizoma Polygonati Odorati | |
| CN105169148B (en) | It is a kind of to treat dyspeptic Chinese medicine and preparation method thereof | |
| CN118403100A (en) | Traditional Chinese medicine composition with lung moistening and cough relieving effects, and preparation method and application thereof | |
| CN104645061A (en) | Medicine for treating blood stasis stationary chronic gastric ulcer and preparation method | |
| CN104888148A (en) | Medicament for chronic hepatitis B | |
| CN104127659A (en) | Traditional Chinese medicine for treating chronic pharyngitis | |
| CN111617227A (en) | Traditional Chinese medicine for treating pestilence qi infection | |
| CN104435985A (en) | Traditional Chinese medicine composition for treating diabetic gastro paresis | |
| CN113908233A (en) | Traditional Chinese medicine composition for relieving defecation dysfunction caused by spinal cord injury | |
| CN102327426A (en) | Medicament for treating chronic enteritis and preparation method thereof | |
| CN106421508A (en) | Traditional Chinese medicine composition for treating heat-type asthma | |
| CN111329911A (en) | Application of angelica sinensis tablets in preparation of product for treating postpartum anemia | |
| CN105169303A (en) | Liver-soothing and qi-regulating preparation for treating stomach distension and preparation method thereof | |
| CN105902822A (en) | Navel moxibustion qi circulation promoting and pain stopping synergistic patch and preparation method thereof | |
| CN105056000A (en) | Medicament beneficial to weight loss and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |